Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 7 sales; 105 institutions reported holding it in 13F filings for Q3 2026, worth $495.1M in total; no superinvestor holds it.
Holders of 5% or more of MNPR
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Monopar Therapeutics, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Janus Henderson Group PLC | 13G/A | 16.70%1.12M shares | −2.80 ppfrom 19.50% | Nov 6, 20246 filings | Nov 16, 2026 | SEC |
| Ra Capital Management, L.P. | 13G/A | 9.90%667.6K shares | 0.00 ppfrom 9.90% | Oct 31, 20244 filings | Feb 17, 2026 | SEC |
| AstraZeneca PLC | 13G/A | 7.80%522.7K shares | – | Oct 28, 20242 filings | Feb 6, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.03%338.1K shares | New | Oct 27, 20261 filing | Oct 27, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
24 Schedule 13D and 13G filings on Monopar Therapeutics, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 202612:24 PM ET | Janus Henderson Group PLC | 13G/A | 16.70%1.12M shares | −2.80 ppfrom 19.50% | Sep 30, 2026 | SEC |
| Oct 27, 20265:25 PM ET | BlackRock, Inc. | 13G | 5.03%338.1K shares | New | Sep 30, 2026 | SEC |
| Aug 12, 20266:26 PM ET | Saturn V Capital Management LLCand 1 other | 13G/A | 4.70%313.4K shares | −0.50 ppfrom 5.20%Below 5% | Jun 30, 2026 | SEC |
| Aug 12, 202612:05 PM ET | Adage Capital Management, L.P.and 2 others | 13G/A | 4.76%324.2K shares | −1.47 ppfrom 6.23%Below 5% | Jun 30, 2026 | SEC |
| May 15, 20261:26 PM ET | Saturn V Capital Management LLCand 1 other | 13G | 5.20%345.6K shares | New | Jan 5, 2026 | SEC |
| May 13, 20269:10 AM ET | Adage Capital Management, L.P.and 2 others | 13G/A | 6.23%424.2K shares | −3.63 ppfrom 9.86% | Mar 31, 2026 | SEC |
| Feb 17, 20264:37 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%667.6K shares | 0.00 ppfrom 9.90% | Dec 31, 2025 | SEC |
| Feb 6, 20269:54 AM ET | AstraZeneca PLCand 1 other | 13G/A | 7.80%522.7K shares | – | Dec 31, 2025 | SEC |
| Jan 30, 20262:32 PM ET | Tactic Pharma LLCand 2 others | 13D/A | 4.50%307.4K shares | −3.00 ppfrom 7.50%Below 5% | Jan 28, 2026 | SEC |
| Nov 14, 20254:16 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%742.9K shares | 0.00 ppfrom 9.90% | Sep 30, 2025 | SEC |
| Nov 14, 202512:49 PM ET | Janus Henderson Group PLCand 1 other | 13G/A | 19.50%1.29M shares | +0.30 ppfrom 19.20% | Sep 30, 2025 | SEC |
| Sep 24, 20258:59 PM ET | Tactic Pharma LLCand 4 others | 13D/A | 7.50%506.2K shares | – | Sep 24, 2025 | SEC |
| Aug 14, 202510:58 AM ET | Janus Henderson Group PLCand 1 other | 13G/A | 19.20%1.17M shares | +0.60 ppfrom 18.60% | Jun 30, 2025 | SEC |
| May 14, 202511:59 AM ET | Janus Henderson Group PLCand 1 other | 13G/A | 18.60%1.13M shares | +1.40 ppfrom 17.20% | Mar 31, 2025 | SEC |
| Feb 14, 20256:25 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%620.1K shares | – | Dec 31, 2024 | SEC |
| Feb 14, 20254:00 PM ET | Tang Capital Management LLCand 4 others | 13G/A | 0.00%0 shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 12, 20259:45 AM ET | Adage Capital Management, L.P.and 2 others | 13G | 9.86%599.2K shares | New | Dec 31, 2024 | SEC |
| Jan 8, 202511:38 AM ET | Janus Henderson Group PLCand 1 other | 13G/A | 17.20%1.05M shares | – | Dec 31, 2024 | SEC |
| Dec 17, 2024 | Tactic Pharma LLC | 13D/AOld format | – | – | – | SEC |
| Nov 6, 2024 | Janus Henderson Group PLC | 13GOld format | – | New | – | SEC |
| Oct 31, 2024 | Ra Capital Management, L.P. | 13GOld format | – | New | – | SEC |
| Oct 28, 20246:00 AM ET | AstraZeneca PLC | 13GOld format | – | New | – | SEC |
| Oct 24, 2024 | Tang Capital Management LLC | 13GOld format | – | New | – | SEC |
| Jun 2, 2023 | Klunzinger Jeffrey R. | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
11 notices from officers, directors and other affiliates planning to sell Monopar Therapeutics shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Oct 1, 20264:37 PM ET | Christopher StarrDirector | 16.8K | $1.34M | Oct 1, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Sep 24, 20264:40 PM ET | Chandler RobinsonDirector · Officer | 29.1K | $2.60M | Sep 24, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Aug 26, 20264:19 PM ET | Patrice RiouxActing Chief Medical Officer | 1 | $110.82 | Aug 26, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Aug 26, 20264:18 PM ET | Kim TsuchimotoDirector | 8.18K | $906.5K | Aug 26, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Aug 25, 20264:44 PM ET | Raymond William AndersonDirector | 6.28K | $699.8K | Aug 25, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Jul 10, 20266:01 PM ETAmended | Arthur KlausnerFormer Board Member | 5.00K | $477.0K | Jul 8, 2026 | MLPFS | SEC |
| Dec 19, 20254:00 PM ET | Arthur KlausnerBoard Member | 5.12K | $343.9K | Dec 18, 2025 | MLPFS | SEC |
| Jul 14, 202512:29 PM ET | Starr Christopher MDirector | 16.8K | $672.0K | Jul 14, 2025 | Merrill Lynch Pierce Fenner & Smith Inc. | SEC |
| Jul 14, 202512:26 PM ET | Tsuchimoto Kim RDirector | 8.90K | $356.2K | Jul 14, 2025 | Merrill Lynch Pierce Fenner & Smith Inc. | SEC |
| Jul 14, 202512:21 PM ET | Robinson ChandlerOfficer · Director | 16.8K | $672.0K | Jul 14, 2025 | Merrill Lynch Pierce Fenner & Smith Inc. | SEC |
| Apr 2, 202511:45 AM ET | Tactic Pharma LLC10% stockholder | 33.3K | $1.17M | Apr 2, 2025 | Merrill Lynch, Pierce, Fenner & Smith, Inc. | SEC |